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Abstract
Endothelial dysfunction reflects pathophysiological changes in the phenotype and functions of 
endothelial cells that result from and/or contribute to a plethora of cardiovascular diseases. Here 
we review the role of hydrogen sulfide (H2S) in the pathogenesis of endothelial dysfunction, one 
of the fastest advanced and hottest research topics. Conventionally treated as an environment 
pollutant, H2S is also produced in endothelial cells and participates in the fine regulation of 
endothelial integrity and functions. Disturbed H2S bioavailability has been suggested to be a novel 
indicator of the progress and prognosis of endothelial dysfunction. Endothelial dysfunction 
appears to exhibit in different forms in different pathologies but therapeutics aimed at remedying 
the altered H2S bioavailability may benefit all.
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From the endothelium and for the endothelium
H2S is a pungent colourless gas with distinctive rotten-egg smell, often regarded as an 
environmental pollutant and a toxin. Yet H2S can be produced in eukaryotic cells. H2S can 
be made in the endothelium by the enzymatic action of cystathionine γ-lase (CSE) with 
cysteine as the substrate (Glossary Box). There is no solid evidence for the involvement of 
cystathioine β-synthase (CBS) in endothelial production of H2S. By contrast, the 
engagement of 3-mercaptopyruvate sulfurtransferase (MST), as a sulfur-carrying enzyme, 
and cysteine aminotransferase in endothelial production of H2S has been reported [1,2].
Over the last decade, the study on the roles of H2S in the homeostasis of endothelial 
function and in the pathogenesis of EDF has grown exponentially. This research has 
deepened our understanding of the regulation of endothelial function in health and facilitated 
the development of preventive and therapeutic strategies for EDF in cardiovascular diseases. 
This review provides a succinct update on the related progresses and describes the 
challenges and future directions for the field, with a focus on the metabolism and functions 
of H2S in different types of EDF.
Endothelium function and its regulation by H2S
The functional importance of the endothelium is realised by its wide coverage of the inner 
surface of the cardiovascular system, polarised architecture in blood vessels, and 
heterogeneity in its morphology, structure, and gene expression profile at different locations 
of different types of blood vessels [3].
The endothelium protects vasculature from inflammatory damage and provides a 
permeability barrier to control blood volume and its electrolyte content. The endothelium is 
usually where vascular inflammation starts and propagates. Pro-inflammatory cytokines 
upregulate the expression of adhesion molecules in endothelial cells. Leukocyte adhesion 
and rolling on endothelial cells ensue. H2S inhibits vascular inflammation [3,4] via different 
signalling pathways, including the inhibition of p38 and nuclear factor kappa-light-chain-
enhancer of activated B cells (NF-κB), the activation of KATP and BKCa channels as well as 
HO-1 expression [5,6]. Moreover, H2S decreases reactive oxygen species (ROS) levels in 
endothelial cells [7-10], which is achieved partially by scavenging ROS [11] and partially by 
upgrading antioxidant defence machineries. Many antioxidant enzymes, such as catalase, 
superoxide dismutase, glutathione peroxidase, and glutathione-S-transferase, are upregulated 
by H2S [12]. Increased production of reduced glutathione (GSH) also accounts for the 
cytoprotective effect of H2S in endothelial cells [10].
The endothelium offers an anti-coagulation and anti-platelet boundary to inhibit aggregation 
and to maintain blood fluidity and fibrinolysis. H2S donors have been shown to prevent the 
aggregation of platelets [13] and thrombus formation in venules [14].
The endothelium also orchestrates angiogenesis and the vascular remodelling process. H2S 
inhibits vascular smooth muscle cell (VSMC) proliferation and phenotypic change at one 
hand, but on the other hand, it stimulates endothelial replication and migration, conditioning 
endothelial cells toward angiogenesis and self-reparation [15]. Pharmacological inhibition 
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and genetic deletion of CSE in the endothelium reduces migration and sprouting of 
endothelial cells. It has also been shown that the vascular endothelial growth factor (VEGF)-
induced angiogenesis ex vivo was markedly suppressed in aortic rings from CSE-KO mice 
[15].
The endothelium regulates vascular contraction and dilation. Vascular tone is regulated by 
H2S in both endothelium-dependent and –independent manners. Generated from VSMCs or 
delivered by exogenous H2S donors, H2S can directly, independent of the presence of the 
endothelium, open KATP channels in VSMCs to cause vasorelaxation [16]. The elimination 
of CSE expression in mouse endothelia abolished endothelial production of H2S as well as 
acetylcholine-induced endothelium-dependent vasorelaxation [17]. This original observation 
has been confirmed by numerous other studies, demonstrating that H2S is indeed an 
endothelium-derived relaxing factor (EDRF) [18]. Furthermore, the endothelium-dependent 
vasorelaxing effect of H2S is more prominent in peripheral resistance arteries than in large 
conduit arteries, requires membrane hyperplorisation of both endothelial cells and VSMCs, 
and is abolished by the blockade of small to medium conductance KCa channels. With the 
support of other lines of evidence, a characteristic identity of endothelium-derived 
hyperpolarising factor (EDHF) emerges for H2S [19, 20] (Box 1).
The interaction between H2S and NO
The interaction of H2S with nitric oxide (NO) can affect each other's fate and endothelial 
function to different extents (Figure 1). NO inhibits CSE activity by inducing S-nitrosation 
of the enzyme [19], whereas it may induce CSE expression [16, 30]. These seemingly 
opposite effects of NO actually offer more precise control over H2S production by NO at 
different levels. NO may also increase the cellular uptake of cystine, indirectly increasing 
H2S production [25].
Inversely, H2S affects NO production. An earlier study showed that H2S-gassed solution or 
NaHS decreased NO formation, eNOS activity and expression, and L-arginine uptake in 
isolated rat aortas and cultured human umbilical vein endothelial cells. These inhibitory 
effects of H2S could be indirectly mediated by the activation of KATP channels [31]. 
However, more consistent observations in recent years support the stimulatory effect of H2S 
on NO signalling pathway [14, 29, 32-35]. When mice were treated with Na2S, 
immunohistochemistry of ear venule walls showed a significant up-regulation of eNOS 
expression [14]. In vitro treatment of rat corpus cavernosum with NaHS increased eNOS 
mRNA and protein levels and enhanced NO production [35]. The phosphorylation and S-
sulfhydration of eNOS [29, 34, 36] and the dimer formation of eNOS [29] are facilitated by 
H2S and so is NO production [29]. The lack of CSE in CSE-KO mice led to elevated 
oxidative stress, dysfunctional eNOS, diminished NO levels, and exacerbated myocardial 
and hepatic I/R injury, which were restored by acute administration of Na2S [32].
H2S and NO act on many common downstream signalling pathways, and the net outcome 
depends on the integration of the individual effect. NO increases cGMP production via the 
stimulation of soluble guanylyl cyclase. H2S potentiates cGMP accumulation via the 
inhibition of phosphodiesterase [37, 38]. Inhibition of eNOS attenuated H2S-stimulated 
Wang et al. Page 3
Trends Pharmacol Sci. Author manuscript; available in PMC 2016 September 01.
Author M
anuscript
Author M
anuscript
Author M
anuscript
Author M
anuscript
vasorelaxation, and silencing CSE abolishes NO-stimulated cGMP accumulation and 
angiogenesis [36]. Different from this synergistic effect of H2S and NO, NO-induced S-
nitrosation of eNOS decreases NO production and H2S-induced S-sulfhydration of the same 
increases NO formation [29].
Do NO and H2S have a direct reaction when presented simultaneously in cellular milieu? 
Earlier study predicted this being likely and an S-nitrosothiol intermediate could be formed 
[26]. At physiological pH, H2S may react with NO to form S-nitrosothiols, thereby limiting 
the vasorelaxing (and perhaps pro-angiogenic) activity of NO. Under acidic conditions 
(pH<7.0), H2S/HS- was capable of inducing the release of NO from oxidised nitrogen 
species (such as NaNO2) or NO derivatives (such as SNP) [27]. Whether such an interaction 
of H2S and NO derivatives, however, occurs under physiological in vivo condition has not 
been directly demonstrated. An unstable molecule thionitrous acid (HS–NO) was proposed 
as the product of the interaction between H2S and S-nitrosothils [27, 28]. Another study 
showed that an anaerobic reaction of NO and H2S led to the oxidation of H2S, depletion of 
NO, and generation of nitroxyl (HNO) [39]. The actual chemical reactions by which H2S 
facilitates the transformation of NO to HNO has been unclear, and other intermediates, such 
as HS-NO, may be involved.
Not being a separate entity of disease, EDF reflects pathophysiological changes in the 
phenotype and functions of endothelial cells that result from and/or contribute to various 
cardiovascular diseases. Also, EDF is not necessarily a generalised pathologic condition and 
may be limited to certain blood vessels in different situations. Decreased NO bioavailability 
has been used as a hallmark of EDF but, depending on the types of blood vessels and the 
pathogenic conditions of EF, the changes in NO bioavailability may not be causatively 
linked to all subtypes of EDF. For example, EDF due to decreased EDHF may be indicated 
by endothelial H2S bioavailability, rather than endothelial NO bioavailability. In the cases 
where NO-dependent endothelial functions, such as acetylcholine-dependent vasodilation of 
conduit artery, remain normal, the change in H2S-dependent endothelium-dependent 
vasorelaxation causes abnormality in EDF [17]. Moreover, as aforementioned, endothelial 
NO metabolism can be significantly affected by H2S (Figure 1). Therefore, disturbed H2S 
bioavailability and physiological functions may serve as another novel indicator of the 
progress and prognosis of EDF. With different pathogenic causes and consequences but a 
common underlying pathology, EDF in various cardiovascular diseases may be differently 
related to H2S metabolism but all benefit from strategies that aim at correcting the altered 
H2S bioavailability (Figure 2).
H2S-related EDF in atherosclerosis
Atherosclerosis is a systemic and chronic vascular disease of large- and medium-sized 
arteries. Pro-atherosclerotic factors, such as high blood pressure, inflammatory factors, lipid 
accumulation, and hyperhomocysteinemia, cause focal endothelial dysfunction. This early 
event triggers artery inflammatory responses, platelet deposition, macrophage 
differentiation, and foam cell formation. Smooth muscle cell proliferation and migration, 
extracellular matrix protein synthesis, and thrombus formation ensue. As such, to prevent or 
correct EDF would be a primary target for atherosclerosis management. Deficiency in CSE 
Wang et al. Page 4
Trends Pharmacol Sci. Author manuscript; available in PMC 2016 September 01.
Author M
anuscript
Author M
anuscript
Author M
anuscript
Author M
anuscript
expression and H2S bioavailability are causatively linked to the development of 
atherosclerosis. Feeding CSE-KO mice with atherogenic paigen-type diet elicited early 
development of fatty streak lesions in the aortic root and increased aortic intimal 
proliferation [40].
Decreased endothelial H2S bioavailability disarms the endothelium from H2S protection 
against EDF in atherosclerosis with multiple mechanisms. For example, H2S has a role in 
maintaining normal lipid metabolism. The fat-fed CSE-KO mice with decreased H2S 
production showed elevated plasma levels of total cholesterol and low-density lipoprotein 
(LDL)-cholesterol and hyperhomocysteinemia, which were corrected by NaHS treatment 
regime [40, 41]. H2S is also involved in decreasing leukocyte adhesion and infiltration into 
the vessel. H2S-generating compounds (NaHS or GYY4137) inhibited NF-κB-mediated 
intercellular adhesion molecule-1 (ICAM-1) expression [42] or CX3CR1 and CX3CL1 
expression in atherosclerosis [43]. Vascular endothelial cells from CSE-KO mice had 
increased expression of adhesion molecules (P-selectin and E-selectin) and integrins 
(ICAM-1 and VCAM-1) [40].
H2S also acts to regulate sheer stress and blood viscosity. Atherosclerosis is unevenly 
developed along the arterial vascular tree partially due to changed patterns of blood flow and 
sheer stress. The branches and curvatures of vasculatures are athero-susceptible regions 
where laminar sheer stress transforms into irregular and swiveled one and these locations are 
mostly prone to develop EDF and atherosclerosis [44]. Oscillatory shear stress-mediated 
monocyte binding to endothelial cells and vasodilation were inhibited by H2S in the 
presence of functional eNOS. On the other hand, H2S increased sheer stress-dependent 
eNOS expression and decreased expression of ICAM-1 [45, 46]. It appears that both H2S 
and NO are involved in the sheer stress-mediated development of atherosclerosis. Increased 
platelet aggregation due to decreased endothelial H2S bioavailability may also contribute to 
changed blood viscosity in atherosclerosis. H2S may also protect the endothelium through 
antioxidant modulation. During atherosclerosis development, monocytes-derived 
macrophages are recruited into the nascent atheromatous lesion and ingest oxidised low 
density lipoproteins (ox-LDL) to become foam cells and to form fatty streaks within artery 
wall. CSE-KO mice fed with atherogenic paigen-type diet had clearly enhanced oxidative 
stress and increased level of ox-LDL in the sub-endothelial space [40]. Supplementations of 
NaHS or GYY4137 attenuated H2O2 and ox-LDL-mediated endothelial cytotoxicity [47, 
48].
H2S-related EDF in diabetic vascular complications
EDF is one of the most important underlying factors for diabetic micro-and 
macroangiopathy. Increased polyol pathway flux, diacylglycerol formation, protein kinase C 
activation, and the production of advanced glycation end-products are putative mechanisms 
for diabetic EDF [49].
Circulating H2S levels are lower in animal models of diabetes, such as streptozotocin-
induced diabetic rats [50, 51] and non-obese diabetic mice [52], and in type 2 diabetic 
patients [50, 53]. As discussed below, the accuracy of measuring circulating H2S level is a 
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significant challenge. Therefore, the correlation of circulating H2S levels with diabetic EDF 
cannot be concluded yet. However, CSE mRNA is unaltered in the thoracic aorta of diabetic 
rats [54]. There are also no changes in the expression of CSE, CBS or MST in endothelial 
cells exposed to elevated extracellular glucose, or in the thoracic aorta of streptozotocin-
diabetic rats [50, 55]. In fact, CSE expression in cerebral microvessels was increased in type 
I diabetes [56].
What, then, are the molecular mechanisms for the lower circulating H2S levels in diabetes 
with increased or unaltered expression of H2S-generating enzymes? Recent data indicate 
that the endothelial MST was inhibited or inactivated during hyperglycemia, leading to 
impaired endothelial cell H2S production, suppressed angiogenesis and attenuation of 
mitochondrial function [55]. Moreover, cellular levels of H2S are determined by the balance 
of its production and consumption/elimination [57]. When endothelial cells are placed in 
elevated extracellular glucose, H2S consumption is increased [50]. This increase can be 
attenuated by either treatment of the cells with ROS scavengers or with mitochondrial 
uncoupling agents, pointing to the importance of mitochondria-derived ROS in the process 
of increased H2S consumption in hyperglycemia [51]. It is likely, therefore, that lower 
circulating H2S level in diabetes is partially related to the oxidative inactivation of 
endothelial MST, and partially to an increased H2S consumption in hyperglycemic 
endothelial cell (Figure 3).
Inhibition of endothelial H2S production exacerbates ROS production in response to 
hyperglycemia [51], which was reversed by supplementation of NaHS [50]. Increased ROS 
consumes intracellular H2S, which then creates additional mitochondrial dysfunction. Such a 
positive-feed-forward cycle may play an important role in the development of EDF by 
activation of mitochondrial cell death signalling (e.g. caspase activation, increased Bax, and 
decreased Bcl-2 protein expression [58], upregulation of endothelial cell adhesion molecules 
(e.g. ICAM-1) [59] and downregulation of gap junction proteins (e.g. Cx43 and Cx40) [60]. 
H2S deficiency may also play a role in the upregulation of the production of endothelin by 
hyperglycemic endothelial cells [61].
H2S-related EDF in sepsis
While the precise mechanisms responsible for EDF in sepsis are incompletely understood, 
inflammatory mediators including cytokines, chemokines, and NO have been implicated. 
Probably due to the presumed similarities of H2S and NO, impact of H2S in sepsis has 
gained significant attention [62,63]. Although early studies reported that sepsis increases 
endogenous H2S production in human patients and experimental models of sepsis [65], more 
recent studies showed depressed levels of free H2S in experimental sepsis. [62, 64]. Time 
and context-dependent changes in the levels of H2S and its metabolites as well as that in 
H2S-generating enzymes during sepsis remain to be clarified [65].
As in the case of NO, H2S likely exerts a wide spectrum of effects during inflammation in a 
concentration-dependent fashion; low sulfide concentrations are anti-inflammatory [65] 
while high sulfide levels are pro-inflammatory [66]. Along these lines, a recent study 
showed that breathing H2S gas exerted beneficial effects in endotoxemic mice by 
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maintaining physiological levels of sulfide and thiosulfate, a major oxidation metabolite of 
H2S [62]. The protective effects of H2S inhalation were associated with inhibition of LPS-
induced inflammatory cytokine induction and marked upregulation of anti-inflammatory 
cytokine IL-10 in the liver.
Acute lung injury (ALI) is characterized by lung inflammation and increased pulmonary 
vascular permeability. Sepsis is a major cause of ALI. Studies have revealed that vascular 
endothelium plays a crucial role in mediating inflammatory response in the lung [67]. 
Therefore, pulmonary vascular endothelium represents one of the major therapeutic targets. 
Since the beneficial effects of H2S inhalation during sepsis was associated with increased 
thiosulfate levels and administration of sodium thiosulfate (NaS2O3, STS) per se prevented 
septic shock and acute liver failure in mice [62], we hypothesised that thiosulfate may be a 
“carrier molecule” of H2S bioactivity (Figure 4). In a recent study, administration of STS 
markedly prevented the lipopolysaccharide (LPS)-induced ALI in mice [68]. STS inhibited 
sepsis-induced production of inflammatory cytokines, lung permeability, histological lung 
injury, and NFκB activation in the lung. In endothelial cells, STS increased intracellular 
levels of sulfide and sulfane sulfur, inhibited LPS or TNFα-induced increase in endothelial 
permeability and production of cytokines and ROS. Considering the clinical availability and 
established safety track record of STS, these observations may have clinically relevance.
H2S-related EDF in stroke
EDF is a risk factor for stroke, a cerebrovascular accident, being a leading cause of death 
worldwide and the primary cause of disability in the western world [69]. While the role of 
altered brain H2S metabolism in stroke-induced neuronal injury is controversial, this review 
will focus on H2S-related EDF in stroke.
The disruption of the blood-brain barrier (BBB), formed by capillary endothelial cells, is a 
hallmark of stroke and contributes significantly to ischaemic brain damage. The protective 
effects of H2S for cerebrovascular endothelial cell function was shown in a study in which 
H2S donors, such as 5-(4-methoxyphenyl)-3H-1,2-dithiole-3-thione (ADT), robustly 
protected BBB integrity and suppressed local neuroinflammation following middle cerebral 
artery occlusion (MCAO), mediated at least in part through inhibition of NF-κB activation 
[70]. In another study, NaHS treatment significantly increased neurovascular endothelial cell 
synthesis and cellular expression of VEGF and angiopoietin-1 around the ischaemic lesion 
post-MCAO and induced capillary-like tube formation and endothelial cell migration in 
vitro, through AKT and ERK-dependent mechanisms [71]. These studies suggest that H2S-
based therapeutic strategies may help maintain BBB integrity and decrease EDF-related 
stroke damage. In the same line, studies on human cerebral microvascular endothelial cells, 
used frequently as an in vitro model of the BBB, showed that slow-release and 
mitochondria-targeted H2S donors such as GYY4137 and AP39, respectively, prevented 
cellular and mitochondrial oxidative damage [72, 73].
The effects of exogenous H2S donors and endogenously produced H2S seem to be different 
on stroke-related EDF without clear mechanistic explanations. For example, CSE-KO mice 
and the mice treated topically with inhibitors of CSE and MST were resistant to post-
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ischaemic cerebral vasodilation, hyperaemia and early BBB disruption following transient 
focal cerebral ischaemia. The hypothetic explanation of this phenomenon is that there was 
excessive and detrimental vascular overproduction of H2S during reperfusion, leading to 
hyperaemia-induced BBB damage [74].
H2S-related EDF in hypertension
H2S-related EDF plays a critical role in the pathogenesis of essential hypertension. The 
expression of CSE in blood vessels of spontaneously hypertensive rats was lower and 
correlated with blood pressure levels [75, 76]. Treatment of hypertensive rats with 
zofenopril, a sulfur containing ACE inhibitor that also acts as a H2S donor, restored 
endothelium-dependent relaxation [75]. Salt-sensitive hypertensive rats exhibited a down-
regulation of CBS in renal tissues [77]. In dexamethasone-induced hypertension model, CSE 
expression was downregulated in resistance vessels [78]. Changes in the expression of H2S-
generating enzymes in all of the above animal experiments were paralleled with lower H2S 
bioavailability. Clinically, grade-2 and grade-3 hypertension patients [79] and diabetic 
patients with hypertension [80] have lower plasma H2S concentrations. Beyond the 
aforementioned correlative studies, a causative relationship between H2S-related EDF and 
hypertension was established by the observation that genetically eliminating CSE expression 
resulted in age-dependent development of hypertension in mice [17]. In these CSE-KO 
mice, endothelium-dependent relaxation of resistance mesenteric arteries was essentially 
abolished [17].
In a model of Ang-II-induced hypertension, administration of NaHS reversed deficits in 
EDF and NO bioavailability, limited endothelial ROS production, and attenuated the 
increase in systolic blood pressure. Inhibition of endogenous production of H2S exacerbated 
the above-mentioned parameters [81]. In other studies, administration of H2S donors to 
hypertensive animals lowers mean arterial blood pressure and reverses vascular remodeling 
by inhibiting VSMC proliferation and collagen accumulation in the vessel wall [1, 16, 
82-84].
H2S-related EDF in preeclampsia
One third of all maternal deaths and premature delivery worldwide are due to preeclampsia 
[85]. The long-term risk of premature death increases by almost 3-fold if the mother has had 
severe preeclampsia [86]. Preeclampsia is a pregnancy-specific multi-organ syndrome 
characterised by widespread endothelial damage and the onset of new hypertension with 
proteinuria after 20 weeks of gestation. The disruption of endothelial homeostasis due to 
dysregulation of cytoprotective pathways and loss of VEGF activity due to increase in anti-
angiogenic factors, soluble Flt-1 (sFlt-1) and soluble endoglin (sEng), are increasingly 
recognized as fundamental features of preeclampsia [87, 88].
CSE and CBS are expressed in the utero-placental unit [89]. A recent study showed that the 
CSE pathway inhibits release of sFlt-1 and sEng from endothelial cells and human placenta 
[90]. Endothelial siRNA knockdown of CSE increased, whereas adenoviral-mediated CSE 
over-expression inhibited, the release of sFlt-1 and sEng from endothelial cells. 
Furthermore, inhibition of CSE activity increased blood pressure and sFlt-1 and sEng levels, 
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and decreased fetal growth in pregnant mice. These symptoms were reversed by GYY4137, 
demonstrating that the effects were due to inhibition of H2S production [90]. A subsequent 
study showed that NaHS attenuated sFlt-1-induced hypertension and renal damage in non-
pregnant Sprague-Dawley rats [91].
One of the mechanisms for H2S-offered protection against acute myocardial ischaemia/
reperfusion injury is the upregulation of the VEGF–Akt–NOS3–NO pathway [92]. 
Interestingly, human placental explants subjected to ischaemia-reperfusion showed down-
regulated CSE expression [93]. Recently, VEGF receptor-2 was reported as the direct target 
of H2S, and VEGF receptor inhibitor suppressed angiogenesis induced by H2S [94]. These 
findings indicate that H2S promotes angiogenesis via VEGF receptor activation. The 
lowered plasma H2S level in pregnant women with preeclampsia coincides with decreased 
circulating placental growth factor levels in women with preeclampsia as both are linked to 
dysregulation of CSE/H2S signaling pathway [90]. H2S supplementation not only restored 
placental vasculature in CSE-inhibited pregnant mice but also improved the lagging fetal 
growth [90]. Thus, endogenous H2S is required for healthy placental vasculature and a 
decrease in CSE/H2S activity may contribute to the pathogenesis of preeclampsia and fetal 
growth restriction.
Besides CSE, the only other enzyme identified to inhibit sFlt-1 and sEng is heme 
oxygenase-1 (HO-1) through its products, carbon monoxide (CO) and bilirubin [95, 96]. 
When both CSE and HO-1fail, the negative feedback loop is lost, and the anti-angiogenic 
factors (sFlt-1 and sEng) go into overdrive, leading to preeclampsia (Figure 5). The 
relationship between CSE and HO-1 remains unexplored and is a subject of great interest.
Concluding Remarks
We have come a long way in understanding the pivotal importance of H2S bioavailability in 
the endothelium. H2S regulates endothelial proliferation and endothelium-dependent 
vascular functions. Decreased H2S bioavailability has been consistently reported in different 
subtypes of EDF. The correlation has been made based on the changes in endothelial 
functions due to reduced gene expression or activity of H2S-generating enzymes in the 
endothelium [9, 17, 40], the relative changes in H2S levels before and after the occurrence of 
EDF using the same measurement method under the same experiment conditions, and the 
actual levels of H2S in the blood and the endothelium. Can we confidently conclude that 
H2S bioavailability is a novel hallmark of EDF? In contrast to the well documented role of 
NO in EDF, there is still a long way to go to establish the similar role of H2S in EDF before 
we can successfully address multi-faceted challenges we are facing.
The concentration of H2S in the circulation and in specific vasculature beds has been one of 
the important parameters used in the literature for correlating the changes in endothelial H2S 
bioavailability with the development of EDF. However, the use of this parameter, especially 
the blood H2S level, is problematic in two aspects. One is that H2S produced in non-
endothelial cells may contribute to its circulation level. As such, the blood H2S level does 
not necessarily reflect actual endothelium H2S bioavailability. The same is true when the 
blood level of NO is used as a biomarker for EDF. The other problem is the accuracy and 
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interpretation of H2S measurement. Since the appropriate and reliable methodology for 
measuring H2S levels in aquatic milieu is still in the developmental stage, there is no 
universally accepted method to assess H2S level and there is no consensus on the 
physiological range for H2S in the blood. In any rate, more recent studies report blood H2S 
levels in the higher nanomolar to lower micromolar range under physiological conditions 
[99, 100]. It also becomes generally acknowledged that blood H2S levels above the higher 
micromolar range will be either toxic or artifact, and would certainly not be physiologically 
relevant. For these considerations, one should be cautious in linking the reported values of 
blood H2S levels to EDF and, in the same reasoning, to many other types of diseases. The 
changes in endothelial expression and activities of H2S-generating enzymes and the 
detection of relative changes in H2S levels in endothelial cells appear to be more meaningful 
in evaluating the role of endothelial H2S bioavailability in EDF.
The therapeutic intervention to restore H2S bioavailability may effectively remedy certain 
types of EDF but also take the risk of perturbing endothelial integrity and function of the 
otherwise normal vasculature in nearby or more remote normal organs. For example, 
supplementation of H2S may promote angiogenesis in the ischaemia-damaged tissues but it 
may spillover to induce vascularisation in other healthy organs and systems. The 
pathogenesis mechanisms of different types of EDF, the specifically affected vasculature in 
EDF, and the progress of the vascular disease (chronic versus acute) should be all taken into 
consideration when designing and applying H2S-releasing compounds and their delivery 
tools and paths. Monitoring the concentrations of H2S in the circulation and in specific 
vasculature beds is also critical for the therapeutic purpose. The readers are referred to some 
recent articles for more detailed discussion on our current understanding on the 
physiological levels of H2S and the H2S-based therapeutic approaches [97, 99, 100]. Other 
major challenges in the field are briefly described in Box 2.
It is anticipated that a better understanding of the regulatory mechanisms of endothelial H2S 
bioavailability will help accelerate the translation of advances in H2S biology to clinical 
management of the EDF-related cardiovascular diseases. For now, endothelial dysfunction 
(EDF) remains the Achilles heel in cardiovascular diseases. “Should his heel have been 
shielded from the poisonous Trojan arrow, Achilles would have been immortal.”
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Glossary Box
AP39 A mitochondria-targeted H2S donor shown to prevent 
endothelial cell (and mitochondrial) toxicity induced by 
oxidative stress at low nM concentrations. It also stimulates 
cellular bioenergentics and lowers heart rate and blood 
pressure in hypertensive animals
Cystathionine γ-lase 
(CSE)
An enzyme in the reverse-transsulfuration pathway which uses 
L-cysteine as the substrate to produce H2S
Endothelium-derived 
hyperpolarising factor 
(EDHF)
The endogenous substances produced in the endothelium 
which can cause the hyperpolarisation of juxtaposed vascular 
smooth muscle cells and vasorelaxation
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Endothelium-derived 
relaxing factor (EDRF)
The endogenous substances produced in the endothelium 
which can cause the relaxation of juxtaposed vascular smooth 
muscle cells
Endothelial 
dysfunction (EDF)
A pathophysiological status in the phenotype and functions of 
endothelial cells that results from and contributes to a plethora 
of cardiovascular diseases
Endothelial NO 
synthase (eNOS)
An endothelium-located enzyme that catalyzes the production 
of nitric oxide from L-arginine
Gasotransmitters A class of endogenously produced gaseous molecules with 
importantsignaling functions for cellular homeostasis. These 
include nitric oxide, carbon monoxide, hydrogen sulfide, and 
ammonium
GYY4137 A water soluble slow release H2S donor shown to lower 
systemic blood pressure in rats and mice and induced blood 
vessel relaxation ex vivo by endothelium- and KATP channel-
dependent mechanisms. It also inhibits oxidative stress-
induced mitochondrial and cellular injury in vitro and in vivo
Heme oxygenase-1 
(HO-1)
An inducible enzyme that catalyses the catabolism of heme to 
produce carbon monoxide, iron, and biliverdin. The latter is 
rapidly converted to bilirubin by biliverdin reductase
3-mercaptopyruvate 
sulfurtransferase 
(MST)
An enzyme that transfers the sulfane sulfur from 3-
mercaptopyruvate to other sulfur acceptors. Eventually, the 
bound sulfur is released or reduced to liberate H2S
Oxidised low-density 
lipoprotein (ox-LDL)
Low-density lipoprotein transfers cholesterol and triglycerides 
through the bloodstream to be used by various cells. Its lipid 
component and/or the protein component can be oxidized to 
become ox-LDL. Ox-LDL is a risk factor for vascular 
inflammation, macrophage infiltration, platelet adhesion, and 
atherosclerosis
Placenta growth factor 
(PlGF)
PlGF shares a 53% amino acid sequence homology with 
VEGF and signals exclusively via VEGF receptor-1 and 
stimulates NO and promotes monocyte migration
Reactive oxygen species 
(ROS)
A group of oxygen-containing reactive molecules, which 
participate in cellular signal transduction under physiological 
conditions and become detrimental under pathological 
conditions when ROS are over-produced
Soluble Endoglin 
(sEng)
A soluble, cleaved form of endoglin (CD105; the co-receptor 
for the transforming growth factor-β) produced by the 
proteolytic cleaving action of metalloproteinase MMP-14 in 
the extracellular domain of endothelial cell membrane. It is 
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elevated in the serum of preeclamptic women 8-12 weeks prior 
to clinical onset of the disease and like sFlt-1, inhibits 
capillary morphogenesis
Soluble fms-like 
tyrosine kinase-1 
(sFlt-1 or sVEGFR-1)
sFlt-1 is a splice variant of the fit gene. It is a tyrosine kinase 
protein that deactivates VEGF receptor signaling by mopping 
up VEGF as well as acting as a ‘dominant negative receptor 
inhibitor’ to prevent VEGF receptor dimerization for cell 
signaling
Vascular endothelial 
growth factor (VEGF)
Being a member of the platelet-derived growth factor family 
of cystine-knot growth factors, VEGF stimulates the growth 
and proliferation of vascular endothelial cells, a critical 
process for both vasculogenesis and angiogenesis
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Box 1
Hydrogen sulfide is an endothelium-derived hyperpolarising factor (EDHF)
Endothelium-dependent vasorelaxation is mediated by endothelium-derived relaxing 
factors (EDRF), including nitric oxide (NO), prostacyclin (PGI2) and endothelium-
derived hyperpolarising factor (EDHF).
EDHF has the following characteristics [18, 21]. 1) It is produced in and released from 
endothelial cells to hyperlolarise and relax vascular smooth muscle cells (VSMCs). 2) Its 
vasorelaxant effect is independent of NO/PGI2 pathways. 3) It increases the activities of 
small (SKCa, <10 pS) and intermediate (IKCa channels, 20∼50 pS) conductance calcium-
dependent K+ channels, which are barred by the co-application of charybdotoxin (ChTX) 
and apamin. 4) It has more profound vasorelaxant effect on peripheral resistance arteries 
than conduit arteries. 5) Its vasorelaxant effect may be more potent in females than 
males.
Among nominated EDHF candidates over the last 25 years are hydrogen peroxide, 
arachidonic acid metabolites (such as THETAs and EETs), K+ ion per se, and C-type 
natriuretic peptide [18-22]. However, none of these candidates fully fulfill the role of 
EDHF. Recent studies have provided evidence that H2S is one of the most qualified 
EDHFs.
Endothelium-dependent, but NO/PGI2-independent, relaxation of mesenteric artery from 
rats or mice is mediated by H2S [23,24]. Deficiency in CSE expression eliminated 
methacholine-induced endothelium-dependent relaxation of mouse mesenteric arteries, 
but not that of aorta [20]. VSMCs from CSE-KO mice have lower resting membrane 
potential than that of WT mice [19], indicating the depolarising effect of endogenous H2S 
on VSMCs. Furthermore, methacholine hyperpolarised VMSCs of mesenteric artery 
from WT mice, but not those from CSE-KO mice. This effect of methacholine was 
abolished by co-applied ChTX/apamin. In contrast, methacholine did not alter membrane 
potential of VSMCs of aortae from WT mice or CSE-KO mice. Both methacholine and 
H2S induced greater VSMC hyperpolarisation of female mesenteric arteries of WT mice 
than that of male WT mice [20].
The mechanisms underlying the EDHF role of H2S have been explored. In an autocrine 
mode, endothelial produced H2S activates endothelium-located SKCa and IKCa channels. 
The resulting endothelial hyperpolarisation can evoke VSMC hyperpolarisation by 
electrical coupling through myoendothelial gap junction or by the increased K+ efflux 
that activates VSMC Kir channel and/or Na+/K+-ATPase. In a paracrine mode, 
endothelium-generated H2S is directly released to VSMCs to induce hyperpolarisation of 
VSMC by opening KATP channels in these cells.
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Box 2
Outstanding questions
1. What is the physiological activator for CSE to acutely produce H2S from 
endothelial cells? One of the mechanisms underlying endothelial production of 
H2S is the activation of cholinergic receptors on endothelial cells, which leads to 
increase in [Ca2+]i and the activation of calcium-calmodulin complex. The latter 
stimulates endothelial CSE to produce H2S in mice [17]. Does acetylcholine/
muscarinic receptor exist in rat or mouse vascular endothelium? Two key 
enzymes are expressed in rat vascular tissues and endothelial cells for in situ 
synthesis in and secretion from endothelial cells, choline acetyltransferase and 
vesicular acetylcholine transporter [98]. It is also known that the endothelium of 
rats or mice produces acetylcholine [98]. Both nicotinic acetylcholine receptor 
[98] and M3 muscarinic acetylcholine receptors [101, 102] are expressed in rat 
or mouse vascular endothelia. Are there other endogenous factors that can 
increase [Ca2+]i in endothelial cells to activate CSE? Previous studies have 
shown that only a prolonged increase in [Ca2+]i can induce CSE translocation 
from the cytosol to mitochondria in vascular smooth muscle cells [103]. It is 
rationalized that, therefore, the calcium/calmodulin activation of CSE would 
depend on specific types of stimuli and the kinetics of intracellular calcium 
change.
2. What is the relationship of the changes in blood sheer stress and endothelial H2S 
production? Alteration in the pattern and force of sheer stress has significant 
effect on [Ca2+] i in endothelial cells and, as such, it may offer another 
endogenous regulation mechanism for the activation of endothelial CSE.
3. What are the regulatory mechanisms for endothelial production of H2S by 
MST/CAT pathway? The physiological stimuli for MST activation have not 
been identified. The endothelial expression of MST should also be verified in 
other species from mice up to humans. Moreover, the relative contributions of 
MST and CSE on endothelial H2S production under physiological condition and 
with endothelial dysfunction are not clear.
4. What is the impact of the interaction between H2S and vascular endothelial 
growth factor (VEGF) on endothelial dysfunction? Papapetropoulos et al. 
demonstrated that VEGF stimulates endothelial production of H2S, and both 
H2S and VEGF produced angiogenesis [15]. Conversely, daily injection of 
NaHS into rats for 7 days increased free plasma VEGF level and upregulated 
renal expression of VEGF-A mRNA. The upregulated VEGF pathway was 
believed responsible for the protective effects of H2S against soluble fms-like 
tyrosine kinase-1 (sFLT1)-induced hypertension, proteinuria, and glomerular 
endotheliosis in rats [91]. By upregulating iNOS expression and NO production 
in human keratinocytes, H2S indirectly down-regulates ERK1/2 activation 
thereby resulting in the decrease of VEGF release [104]. The interaction of 
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endothelium-derived endogenous substances such as H2S, CO and NO with 
VEGF in endothelium dysfunction is unknown.
5. How do H2S and CO suppress sFlt-1 and sEng release and protect pregnancy 
[90, 95]? What intermediary pathways are involved in H2S-mediated protection 
against hypertension and kidney and liver injury when VEGF or placenta 
growth factor (PlGF) activity is compromised [90, 91].
6. What is the physiological concentration of endogenous H2S in the endothelium? 
Both the production and removal of H2S need to be better quantitated in the 
endothelium as well as in circulation. Unfortunately, many currently available 
H2S measurement techniques are problematic due to their insufficient accuracy, 
sensitivity, and reliability in detecting H2S levels in the circulation and inside 
the cells. Consequently, there is no consensus on the physiological levels of H2S 
in endothelial cells or in the blood. Another closely related outstanding question 
is the detection of endothelial H2S bioavailability in humans under physiological 
condition and in diseases. Furthermore, the advance in H2S biomedical research 
has been impeded by the lack of suitable pharmacological tools – specific 
inhibitors and activators of H2S-generating enzymes as well as optimized H2S 
donors.
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Highlights
• Endothelial H2S bioavailability regulates endothelial proliferation and function
• H2S is an endothelium-derived hyperpolarising factor
• Altered H2S bioavailability is a novel hallmark of endothelial dysfunction.
• H2S bioavailability is a therapeutic target for remedying endothelial 
dysfunction.
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Figure 1. 
The interaction and convergence of H2S and NO signaling pathways in endothelial function 
regulation. (1) NO may increase the expression of CSE [16], but inhibit the activity of CSE 
[19]. (2) NO may increase the cellular uptake of cystine [25]. (3) NO and H2S may form 
new molecules [26-28]. (4) NO makes its targets resistant to H2S so that H2S cannot modify 
the same targets as it does in the absence of NO [29]. (5) Under acidic condition, H2S 
induces the release of NO from nitrite or other NO derivatives. The solid arrow lines depict 
the stimulatory interactions whereas the dotted arrow lines indicate the inhibitory 
interactions.
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Figure 2. 
H2S signaling and endothelial dysfunction in cardiovascular diseases. Decreased endothelial 
H2S bioavailability contributes to the pathogenesis of all subtypes of EDF discussed. The 
phenotypes of EDF are numbered to facilitate the description. 1 - Barrier and anti-
coagulation. 2 - Angiogenesis and self-repair. 3 - Synthesis and secretion. 4 -Endothelium-
dependent vasorelaxation.
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Figure 3. 
H2S-related pathomechanisms of diabetic endothelial dysfunction. Left side: Vascular 
production of H2S in normal blood vessels is largely due to the physiological activity of 
CSE and MST. Right side: When endothelial cells are placed in elevated extracellular 
glucose, they respond with increased ROS production (from the mitochondrial electron 
transport chain, and other sources, not shown). The increased ROS inhibits the MST 
pathway and (directly and indirectly) enhances the consumption of H2S, leading to a H2S-
deficient cellular state. This, in turn, creates additional mitochondrial dysfunction, which 
produces additional ROS in a positive feedback cycle. DHLA, dihydrolipoic acid; AGE, 
advanved glycation endproducts; PKC, protein kinase C; PARP, poly(ADP-ribose) 
polymerase; 3-MP, 3-mercaptopyruvate; ROS, reactive oxygen species; RNS, reactive 
nitrogen species.
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Figure 4. 
Hypothetical mechanisms responsible for anti-inflammatory effects of endogenous or 
exogenous H2S. H2S may exert its anti-inflammatory effects via modulating a variety of 
signaling mechanisms including NfKB, Nrf-2, or IL-10/JAK/STAT3-dependent signaling. 
Thiosulfate may also exert anti-inflammatory effects. The solid arrow lines depict the 
stimulatory interactions whereas the dotted barbed lines indicate the inhibitory interactions. 
Met, methionine; Hcy, homocysteine; Cys, cysteine; CAT, cysteine aminotransferase; CBS, 
cystathionine beta-synthase; CSE, cystathionine gamma-lyase; MST, 3-mercaptopyruvate 
sulfurtransferase; Nrf2, Nuclear factor (erythroid-derived)-like 2; JAK, janus kinase; STAT, 
signal transducer and activator of transcription; SQR, sulfide quinone oxidoreductase; SDO, 
sulfide dioxigenase; SO, sulfite oxidase; TST, thiosulfate sulfurtransferase.
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Figure 5. 
Defective H2S-CO pathways leading to preeclampsia. Decreased production of hydrogen 
sulfide (H2S) and carbon monoxide (CO) due to the downregulation of cystathionine γ-lyase 
(CSE) and heme oxygenase-1 (HO-1), respectively, lower the levels of soluble Flt-1 (sFlt-1) 
and soluble Endoglin (sEng) and increase placenta growth factor (PlGF) production. These 
alterations constitute pathogenic factors endothelial dysfunction in preeclampsia.
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